The drug surprises the scientific community by eliminating cancer in 100% of cases

Colorectal cancer: Study with drug approved by Anvisa has unprecedented results in eliminating tumor in 100% of cases. “During the median period of 12 months, no patients received chemoradiotherapy and no patients underwent surgical resection”

A drug already approved by Anvisa surprised the scientific community by making colon cancer disappear in 100% of the patients who were being treated. The test, which validated the surprising research, came from a small group of 12 patients with rectal cancer. In them, the researchers locally applied a monoclonal antibody called dostarlimab, which led to the encouraging result and which was maintained for more than a year.

The study was published in the New England Journal of Medicine on Sunday the 5th and discussed by oncologists during the annual event of the American Society of Clinical Oncology (ASCO), which ended Tuesday the 7th. rectal examination or biopsy showed no evidence of the presence of a tumor.

Patients took the drug intravenously every three weeks for six months. “During the median follow-up period of 12 months, no patient received chemoradiotherapy and no patient underwent surgical resection,” reads an excerpt from the study.

In an interview with The New York Times, oncologist Luiz Diaz Jr., one of the authors of the work, says that the success rate of American research is not common, and it may be the first time that something like this has been recorded across the country. history of cancer studies.

“I do not think anyone has seen this before where every patient got the tumor gone,” said oncologist at Memorial Sloan Kettering Cancer Center in New York and lead author of the study Andrea Cercek.

Dostarlimab is approved in Brazil for the treatment of endometrial cancer and had not been tested against other types of tumors until then. Although promising, the study has some caveats, such as the need for long-term follow-up to see if the tumors will not reappear or if metastases will not reappear in other parts of the body.

It is also worth noting that all volunteers carried a specific abnormality in their rectal cancer, popularly known as ‘mismatch repair deficiency’, which prevents the body’s function from normalizing and results in cellular mutations. This type of abnormality occurs in between 5 and 10% of all rectal cancer patients.

Patients with colorectal cancer have a high survival rate, but conventional treatment can cause lifelong sequelae. Examples of comorbidities are: intestinal and bladder dysfunction, sexual dysfunction and even infertility in younger women. Some patients may still need to carry a colostomy bag permanently.

→ IF YOU HAVE MADE IT HERE … consider helping pragmatism continue the work it has done for 13 years, reaching millions of people. Our journalism has always bothered many people, but the attempts to silence it became greater after Jair Bolsonaro’s arrival in power. So it has never made so much sense to ask for your support. Every contribution is important and helps to maintain the team, the structure and the freedom of expression. Click here and support!

Leave a Comment

Your email address will not be published.